Abbott Laboratories vs First Trust Cloud Computing ETF — how do they compare? Abbott Laboratories trades at $110.8 (market cap $187.95B), while First Trust Cloud Computing ETF trades at $161.62. The key difference: Abbott Laboratories pays a 2.32% dividend while First Trust Cloud Computing ETF pays none, and First Trust Cloud Computing ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | SKYY | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | — |
52-Week High | $136.62 | $161.09 |
52-Week Low | $82.57 | $104.16 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
SKYY trades at $161.62, up 0.52% today, with a bullish technical signal from moving averages but overbought RSI levels. The ETF provides diversified exposure to cloud computing, benefiting from AI adoption and cloud migration trends. Recent news highlights strong inflows into technology ETFs and AI-driven growth in cloud infrastructure.
The outlook for SKYY remains positive due to secular tech trends, though overbought conditions and competition from European tech sovereignty initiatives pose risks. Analyst sentiment is generally favorable, focusing on long-term growth in cloud and AI sectors.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →